Indian Physicians Start to Incorporate Targeted Therapies to Achieve Better Efficacy and Toxicity Profiles Than Conventional Therapies, According to a Report From Decision Resources
WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian breast cancer drug market will almost double from $35 million in 2007 to $64 million by 2012. According to the new Emerging Markets report entitled Breast Cancer in India, this growth will be fueled by rising disease prevalence, increasing wealth and growing disease awareness.
The report finds that docetaxel (Sanofi-Aventis's Taxotere, Indian products) and epirubicin (Pfizer's Farmorubicin, Indian products) will continue to be the market leaders, but sales of trastuzumab and bevacizumab (Roche's Herceptin and Avastin), gemcitabine (Eli Lilly's Gemcite, Indian products), and capecitabine (Roche's Xeloda, Indian products) will grow rapidly during this period.
The report also finds that Indian physicians in the six surveyed regions (Delhi, Mumbai, Bangalore, Chennai, Jaipur and Lucknow) are encouraged by the success of targeted therapies in other major markets and have started to increasingly incorporate targeted therapies --- Herceptin, Avastin, GlaxoSmithKline's Tykerb --- into breast cancer treatment to achieve better efficacy and toxicity profiles than conventional therapies. However, premium prices are the major constraint for market uptake.
"India's fast-growing economy will drive demand for novel therapies with higher efficacy and fewer side effects, which usually command high prices, among the burgeoning middle class and higher-income breast cancer patients," added Jing Wu, analyst at Decision Resources.
EMERGING MARKETS REPORTS
The Ultimate Analysis of Pharmaceutical Markets in China and India
Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved